AGWCA
SUPN icon

Annis Gardner Whiting Capital Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.03K Hold
20
– – ﹤0.01% 1144
2025
Q4 		$994 Hold
20
– – ﹤0.01% 1054
2025
Q3 		$956 Hold
20
– – ﹤0.01% 992
2025
Q2 		$631 Buy
+20
New +$641 ﹤0.01% 1151

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's SUPN Position: Q1 2026 in Review

Annis Gardner Whiting Capital Advisors held its Supernus Pharmaceuticals (SUPN) position steady in Q1 2026 at 20 shares worth $1.03K. The position accounts for ﹤0.01% of the portfolio, ranked #1144.

Annis Gardner Whiting Capital Advisors first reported a position in SUPN in Q2 2025 and has held it in 4 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Annis Gardner Whiting Capital Advisors held 20 shares of Supernus Pharmaceuticals worth $1.03K as of Q1 2026.
  • Annis Gardner Whiting Capital Advisors left its Supernus Pharmaceuticals share count unchanged in Q1 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Annis Gardner Whiting Capital Advisors's portfolio in Q1 2026, its #1144 holding.
  • Annis Gardner Whiting Capital Advisors first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.